Skip to main content
. 2015 May;43(5):743–748. doi: 10.1124/dmd.114.062836

Fig. 2.

Fig. 2.

SHP represses PXR and CAR transactivation of CYP3A4 promoter. (A) HepG2 cells were cotransfected with pGL3-CYP3A4 and Renilla luciferase vector, along with expression vectors for GR or SHP. On the next day, the cells were treated with vehicle (DMSO) or dexamethasone (1 μM) for 24 hours, and dual luciferase assays were performed. (B) HepG2 cells were cotransfected with pGL3-CYP3A4 and Renilla luciferase vector, along with expression vectors for PXR or SHP. On the next day, the cells were treated with vehicle (DMSO) or rifampin (5 μM) for 24 hours, and dual luciferase assays were performed. (C) HepG2 cells were cotransfected with pGL3-CYP3A4 and Renilla luciferase vector, along with expression vectors for CAR or SHP. The cell lysates were collected after 24 hours, and dual luciferase assays were performed. **P < 0.01; ***P < 0.001.